Cloud Contradiction: Despite Security Driving Cloud Adoption, Aptum Study Reveals It’s also the Main Barrier to Cloud Transformation
18.1.2021 17:00:00 EET | Business Wire | Press release
While 91% of organizations were successful in increasing security as a result of adopting cloud services, it remains a top concern for many. This finding comes from part two of the four-part Cloud Impact Study from Aptum, the global hybrid multi-cloud managed service provider. The report, titled The Security and Compliance Barricade , identifies common security, compliance and governance challenges impacting organizations undergoing cloud transformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005035/en/
Aptum Cloud Impact Study Pt 2.: The Security and Compliance Barricade (Graphic: Business Wire)
The independent research reveals that more than half of survey respondents (51%) see security as the main driver behind cloud adoption. However, 38% cite security and data protection as the primary barrier to cloud transformation.
Security and compliance play a critical role
Part one of the Cloud Impact Study, Bridging the Cloud Gap , found most survey respondents plan to take a hybridized approach to their cloud infrastructure, with more than half (59%) of respondents saying they will reduce their on-premises infrastructure to some degree and increase public cloud deployments within the next 18-24 months. A further 66% intend to expand their private cloud workloads.
According to data found in today’s report, this expansion and diversification of infrastructure raises security and compliance issues among senior IT professionals, including:
- Control and governance (82%)
- Visibility through a single portal (81%)
- Ability to meet requirements of compliancy audits (80%)
“Organizations are enjoying a newfound agility as they embrace hybrid cloud solutions, but scattered workloads present a security concern," explains Craig Tavares, Global Head of Cloud at Aptum. “A cloud environment is only as secure as the polices and controls an organization has in place, which is why they need to be built into the formation of any cloud strategy. Although no single solution on its own can guarantee 100% security, especially in a multi/hybrid cloud approach, experienced partners can assist organizations in choosing the right combination of security technologies that compliments their workloads no matter where they are hosted and ensure visibility across disparate environments."
“Security teams are tasked with protecting a widening attack surface, often with limited budgets and resources, against bad actors who are employing the same sophisticated techniques as top cybersecurity providers,” said Dan Webb, VP of Partner Sales and Alliances, Alert Logic. “With the ubiquity of cloud and hybrid environments, containerization, and mobile, IoT, and other edge devices, the traditional notion of a perimeter is no more. To be effective, security solutions must enable total visibility across an organization’s IT estate to help organizations quickly identify, prioritize, and respond to all threats that surface.”
Together, Aptum and Alert Logic partner to safeguard business critical data across the infrastructure and application stack, merging security technology, threat intelligence and 24/7 security experts to deliver security outcomes to businesses in an as-a-service model.
The study’s results reinforce the importance of incorporating security into cloud architectures from design through to implementation and transformation. The results call for organizations to take a holistic approach to cloud architectures, with security principles embedded in the design. By doing this, businesses can mitigate threats and minimize risks as they arise to create an environment safer than any on-premise or legacy alternatives.
The full findings of part two of the Cloud Impact Study, The Security and Compliance Barricade, can be found here.
Aptum’s Cloud Impact Study was created from the opinions of 400 senior IT professionals in the US, Canada and UK across industries in financial services, IT, technology, telecommunications, manufacturing, retail, public and commercial sectors. The final two reports will focus on Costs and Budgets and Modernization Opportunities.
For part one of the report, Bridging the Cloud Gap, please visit here.
About Aptum Technologies
Aptum Technologies enables customers to unlock the potential of their data infrastructure to drive tangible business outcomes and maximize the value of their technology investments. Aptum’s Data Center, Cloud, Hosting and Global Network solutions, underpinned with expert Managed and Professional Services, offer genuine choice and adaptability combined with international reach spanning North America, Latin America, Europe and the United Kingdom. Aptum is a portfolio company of Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure. For more information, visit www.aptum.com.
Connect with Aptum
Official Blog| LinkedIn | Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005035/en/
Contact information
Media Contact
Tonique Bedeau, Aptum Technologies
media@aptum.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
